ISSA's program provides trainers and coaches with education about the physical and emotional changes people taking these drugs experience
Then the market hit an inflection point: GLP-1 stopped being metabolic medicine and became a category-defining obesity engine, with downstream effects across payer policy, manufacturing capacity, and portfolio strategy
And many experience uncomfortable side effectsnausea, serious fatigue, or not being able to keep food down
However, it is important to note that the absence of documented interactions does not guarantee that combination therapy is entirely without considerations, particularly regarding side effect profiles
Long-term success is more likely when GLP-1s are paired with a comprehensive care approach that includes clinical oversight, nutrition support, and long-term behavior change strategies